Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024
William G. Wierda(The University of Texas MD Anderson Cancer Center), Mary A. Dwyer(National Comprehensive Cancer Network), Jeremy S. Abramson(Harvard University), Tanya Siddiqi(City Of Hope National Medical Center), Brian T. Hill(Cleveland Clinic), Claudio A. Mosse(Breast Cancer Research Foundation), Sameer A. Parikh(Mayo Clinic in Arizona), Randall S. Davis(University of Colorado Cancer Center), Jennifer A. Woyach(The Ohio State University), Madhav Seshadri(UCSF Helen Diller Family Comprehensive Cancer Center), Nina D. Wagner‐Johnston(Sidney Kimmel Comprehensive Cancer Center), Larry D. Cripe(Indiana University Melvin and Bren Simon Comprehensive Cancer Center), Jennifer R. Brown(Dana-Farber Cancer Institute), Deborah M. Stephens(University of North Carolina at Chapel Hill), Thomas J. Kipps(Moores Cancer Center), Danielle M. Brander(Duke University), Matthew J Cortese(Roswell Park Comprehensive Cancer Center), Christopher D.�M. Fletcher(Harvard University), Farrukh T. Awan(The Ohio State University), Meghan C. Thompson(Memorial Sloan Kettering Cancer Center), Paul Kaesberg(University of Wisconsin–Madison), Brad S. Kahl(UW Health University Hospital), Herbert Eradat(Memorial Sloan Kettering Cancer Center), Sameh Gaballa(Johns Hopkins Hospital), Chaitra S. Ujjani(Fred Hutch Cancer Center), Shuo Ma(Nantong University), Stephen J. Schuster(UPMC Hillman Cancer Center), Bita Fakhri(University of California, San Francisco), Hema Sundar, Muhammad Saad Hamid(Hayatabad Medical Complex), Andrew Schorr(Patient Advocate Foundation), Riccardo Valdez(University of Michigan), Greg Bociek(Susan Thompson Buffett Foundation), Manali Kamdar(University of Colorado Cancer Center), S Bilgrami(Yale Cancer Center), Shazia Nakhoda(Fox Chase Cancer Center)
Cited by 83
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k